Literature DB >> 24106929

Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease.

Krzysztof Kurek1, Dominika M Piotrowska, Patrycja Wiesiołek-Kurek, Bartłomiej Łukaszuk, Adrian Chabowski, Jan Górski, Małgorzata Zendzian-Piotrowska.   

Abstract

BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) is an insulin resistance-related hepatic disorder which can transform to cirrhosis. Insulin resistance deregulates hepatic lipid metabolism, leading to accumulation of cytotoxic lipids including ceramide and diacylglycerols. Myriocin, obtained from fungi traditionally used in Chinese medicine in an effort to attain eternal youth, is a potent pharmacological inhibitor of ceramide de novo synthesis. We examined whether inhibition of ceramide de novo synthesis with myriocin ameliorate hepatic lipid accumulation and reverse NAFLD.
METHODS: The experiment was carried out on male Wistar rats. The animals were divided into four groups: (i) control group, fed standard rodent diet, (ii) group, fed standard diet also treated with myriocin for 7 days, (iii) group, fed high-fat diet for 5 weeks, (iv) group, fed high-fat diet and treated with myriocin. In liver samples sphingolipids: ceramide, sphingosine and sphingosine-1-phosphatate and neutral lipids, such as diacylglycerols and triacylglycerols were measured. In peripheral blood samples, glucose and insulin levels and aminotransferases activities were measured.
RESULTS: High-fat diet feeding caused NAFLD, confirmed by histological assessment, with increased hepatic lipids accumulation and whole-body insulin resistance. After treating with inhibitor of ceramide de novo synthesis, decrease in hepatic ceramide and other toxic lipids were noticed. Moreover, histological analysis of liver samples revealed that inhibition of ceramide de novo synthesis reduced hepatic steatosis.
CONCLUSIONS: Inhibition of ceramide de novo synthesis reduced hepatic lipid accumulation in rats with NAFLD, this led to amelioration of hepatic steatosis.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  ceramide; myriocin; nonalcoholic fatty liver disease; obesity; sphingolipids

Mesh:

Substances:

Year:  2013        PMID: 24106929     DOI: 10.1111/liv.12331

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  56 in total

Review 1.  Sphingosine kinase and sphingosine-1-phosphate in liver pathobiology.

Authors:  Timothy Rohrbach; Michael Maceyka; Sarah Spiegel
Journal:  Crit Rev Biochem Mol Biol       Date:  2017-06-15       Impact factor: 8.250

2.  Withaferin A Improves Nonalcoholic Steatohepatitis in Mice.

Authors:  Daxesh P Patel; Tingting Yan; Donghwan Kim; Henrique B Dias; Kristopher W Krausz; Shioko Kimura; Frank J Gonzalez
Journal:  J Pharmacol Exp Ther       Date:  2019-08-16       Impact factor: 4.030

3.  FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice.

Authors:  Timothy D Rohrbach; Amon Asgharpour; Melissa A Maczis; David Montefusco; L Ashley Cowart; Pierre Bedossa; Arun J Sanyal; Sarah Spiegel
Journal:  J Lipid Res       Date:  2019-05-20       Impact factor: 5.922

Review 4.  Sphingolipids and phospholipids in insulin resistance and related metabolic disorders.

Authors:  Peter J Meikle; Scott A Summers
Journal:  Nat Rev Endocrinol       Date:  2016-10-21       Impact factor: 43.330

5.  Omega-3 PUFA ameliorates hyperhomocysteinemia-induced hepatic steatosis in mice by inhibiting hepatic ceramide synthesis.

Authors:  Yong-Qiang Dong; Xing-Zhong Zhang; Lu-Lu Sun; Song-Yang Zhang; Bo Liu; Hui-Ying Liu; Xian Wang; Chang-Tao Jiang
Journal:  Acta Pharmacol Sin       Date:  2017-09-21       Impact factor: 6.150

6.  An ANGPTL4-ceramide-protein kinase Cζ axis mediates chronic glucocorticoid exposure-induced hepatic steatosis and hypertriglyceridemia in mice.

Authors:  Tzu-Chieh Chen; Rebecca A Lee; Sam L Tsai; Deepthi Kanamaluru; Nora E Gray; Nicholas Yiv; Rachel T Cheang; Jenna H Tan; Justin Y Lee; Mark D Fitch; Marc K Hellerstein; Jen-Chywan Wang
Journal:  J Biol Chem       Date:  2019-05-03       Impact factor: 5.157

7.  Lithium Hydroxide Hydrolysis Combined with MALDI TOF Mass Spectrometry for Rapid Sphingolipid Detection.

Authors:  Anh Tran; Liting Wan; Zhenbo Xu; Janette M Haro; Bing Li; Jace W Jones
Journal:  J Am Soc Mass Spectrom       Date:  2020-10-30       Impact factor: 3.109

Review 8.  Defect of insulin signal in peripheral tissues: Important role of ceramide.

Authors:  Rima Hage Hassan; Olivier Bourron; Eric Hajduch
Journal:  World J Diabetes       Date:  2014-06-15

Review 9.  Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease.

Authors:  Manoela Mota; Bubu A Banini; Sophie C Cazanave; Arun J Sanyal
Journal:  Metabolism       Date:  2016-03-03       Impact factor: 8.694

Review 10.  Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies.

Authors:  Giovanni Musso; Maurizio Cassader; Roberto Gambino
Journal:  Nat Rev Drug Discov       Date:  2016-01-22       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.